Shared on 24 Oct 25
Narrative Update on Biovica International: Analyst Price Target Adjustment Analysts have significantly reduced their price target for Biovica International, citing the company's much lower projected profit margin, even though forecasts for fair value and revenue growth remain stable. What's in the News Biovica International AB completed a follow-on equity offering and raised SEK 80.1 million through the issuance of A and B shares.
Shared on 10 Oct 25
Fair value Decreased 33%DiviTum Entry Will Expand Breast Cancer Treatment Opportunities
Analysts have revised Biovica International’s fair value estimate downward from SEK 1.80 to SEK 1.20. This change reflects more cautious projections for revenue growth and profit margins.
Shared on 19 Aug 25
Fair value Increased 20%DiviTum Entry Will Expand Breast Cancer Treatment Opportunities
The notable upward revision in Biovica International’s fair value reflects a sharp reduction in its future P/E ratio, with the consensus analyst price target rising from SEK1.50 to SEK1.80. What's in the News Completed SEK 80 million rights offering with A and B shares at SEK 0.63 each, including attached warrants; anchor investors subject to a 6-month lock-up post-offering.
Shared on 01 May 25
Fair value Decreased 5.06%DiviTum Entry Will Expand Breast Cancer Treatment Opportunities
Shared on 24 Apr 25
Fair value Increased 5.33%DiviTum Entry Will Expand Breast Cancer Treatment Opportunities
AnalystConsensusTarget made no meaningful changes to valuation assumptions.